186 related articles for article (PubMed ID: 27797376)
1. Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin β1-driven Src-Akt bypass signaling.
Kim YJ; Jung K; Baek DS; Hong SS; Kim YS
Oncogene; 2017 May; 36(18):2543-2552. PubMed ID: 27797376
[TBL] [Abstract][Full Text] [Related]
2. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.
Kim YJ; Baek DS; Lee S; Park D; Kang HN; Cho BC; Kim YS
Cancer Lett; 2019 Dec; 466():23-34. PubMed ID: 31521695
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis.
Kim YJ; Bae J; Shin TH; Kang SH; Jeong M; Han Y; Park JH; Kim SK; Kim YS
J Control Release; 2015 Oct; 216():56-68. PubMed ID: 26260451
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.
Kanda R; Kawahara A; Watari K; Murakami Y; Sonoda K; Maeda M; Fujita H; Kage M; Uramoto H; Costa C; Kuwano M; Ono M
Cancer Res; 2013 Oct; 73(20):6243-53. PubMed ID: 23872583
[TBL] [Abstract][Full Text] [Related]
5. Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling.
Yang D; Tang Y; Fu H; Xu J; Hu Z; Zhang Y; Cai Q
Biochem Biophys Res Commun; 2018 Oct; 505(1):215-221. PubMed ID: 30243721
[TBL] [Abstract][Full Text] [Related]
6. EGFR and β1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion.
Poschau M; Dickreuter E; Singh-Müller J; Zscheppang K; Eke I; Liersch T; Cordes N
Radiother Oncol; 2015 Sep; 116(3):510-6. PubMed ID: 26096850
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
[TBL] [Abstract][Full Text] [Related]
8. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
Nair S; Trummell HQ; Rajbhandari R; Thudi NK; Nozell SE; Warram JM; Willey CD; Yang ES; Placzek WJ; Bonner JA; Bredel M
PLoS One; 2020; 15(2):e0229077. PubMed ID: 32069320
[TBL] [Abstract][Full Text] [Related]
9. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
[TBL] [Abstract][Full Text] [Related]
10. Neuropilin-1-dependent regulation of EGF-receptor signaling.
Rizzolio S; Rabinowicz N; Rainero E; Lanzetti L; Serini G; Norman J; Neufeld G; Tamagnone L
Cancer Res; 2012 Nov; 72(22):5801-11. PubMed ID: 22986738
[TBL] [Abstract][Full Text] [Related]
11. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis.
Zhou R; Curry JM; Roy LD; Grover P; Haider J; Moore LJ; Wu ST; Kamesh A; Yazdanifar M; Ahrens WA; Leung T; Mukherjee P
Oncogene; 2016 Oct; 35(43):5608-5618. PubMed ID: 26804176
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.
Lu Y; Li X; Liang K; Luwor R; Siddik ZH; Mills GB; Mendelsohn J; Fan Z
Cancer Res; 2007 Sep; 67(17):8240-7. PubMed ID: 17804738
[TBL] [Abstract][Full Text] [Related]
13. Assessment of different 3D culture systems to study tumor phenotype and chemosensitivity in pancreatic ductal adenocarcinoma.
Zeeberg K; Cardone RA; Greco MR; Saccomano M; Nøhr-Nielsen A; Alves F; Pedersen SF; Reshkin SJ
Int J Oncol; 2016 Jul; 49(1):243-52. PubMed ID: 27177201
[TBL] [Abstract][Full Text] [Related]
14. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
15. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
Sánchez-Martín FJ; Bellosillo B; Gelabert-Baldrich M; Dalmases A; Cañadas I; Vidal J; Martinez A; Argilés G; Siravegna G; Arena S; Koefoed K; Visa L; Arpí O; Horak ID; Iglesias M; Stroh C; Kragh M; Rovira A; Albanell J; Tabernero J; Bardelli A; Montagut C
Clin Cancer Res; 2016 Jul; 22(13):3260-7. PubMed ID: 26888827
[TBL] [Abstract][Full Text] [Related]
16. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
Wang J; Chan DKW; Sen A; Ma WW; Straubinger RM
Mol Cancer Ther; 2019 Nov; 18(11):2074-2084. PubMed ID: 31363010
[TBL] [Abstract][Full Text] [Related]
17. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
18. Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects.
Borchardt H; Schulz A; Datta K; Muders MH; Aigner A
Sci Rep; 2019 Oct; 9(1):15471. PubMed ID: 31664117
[TBL] [Abstract][Full Text] [Related]
19. A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells.
Jung K; Kim JA; Kim YJ; Lee HW; Kim CH; Haam S; Kim YS
Cancer Immunol Res; 2020 Jan; 8(1):46-56. PubMed ID: 31554638
[TBL] [Abstract][Full Text] [Related]
20. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]